ATTENTION DEFICIT HYPERACTIVITY DISORDER TREATMENT MARKET ANALYSIS

Attention Deficit Hyperactivity Disorder Treatment Market, by Drug Type (Stimulants (Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, Lisdexamfetamine Dimesylate), Non-stimulants (Atomoxetine, Bupropion, Guanfacine, Clonidine)), by Age Group (Pediatric and Adolescent, Adult), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Oct 2022
Code : CMI830
Pages :181
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Attention Deficit Hyperactivity Disorder Treatment: Key Developments

In September 19, 2022, Cingulate, a biopharmaceutical company that focused on the development of new product candidates for the treatment of central nervous system and neurobiological disorders, presents data for its product candidate called CTx-2103, an extended release tablet of busporin used for treatment of anxiety related disease like attention deficit hyperactivity disorder in children as well as adults.

In July 2021, Adlon Treatment L.P., a subsidiary of Purdue Pharma L.P., a specialty pharmaceutical company committed to provide treatment options for patients who suffer from the symptoms of Attention Deficit/Hyperactivity Disorder (ADHD), announced the approval of supplement new drug application for ADHANSIA XR(methylphenidate HCI) extended release capsules CII for treatment of ADHD. ADHANSIA XR capsule contains multilayered beads, composed of immediate release layer and 20 percent of methylphenidate dose.